bioRxivBiochemistryPreprint
PBRM1 is a vulnerability in ARID1A deficient multicellular tumor spheroids
T. Chakravarty, K. D. Tran, D. Dhamecha, T. Perdue, J. L. Garzon, J. Menon, A. Dutta
Abstract
ARID1A, a subunit of SWI/SNF, has been shown to play a major role in recruitment of the chromatin remodeler to enhancers for transcriptional regulation. Mutations inARID1A have been found in various cancers, many of which form solid tumors. Recent studies have revealed vulnerabilities in cells lacking ARID1A, specifically ARID1B, an ortholog and mutually exclusive subunit, in 2D cell culture. However, identification of vulnerabilities within SWI/SNF for loss of ARID1A in a multicellular tumor spheroid, that mimic in vivo condition within tumors, has not been explored. Here we show in the absence of ARID1A in a MTS model, ARID1B continues to be a vulnerability but we have identified PBRM1 as a new vulnerability within SWI/SNF. Levels of ARID1B and PBRM1 are elevated on loss of ARID1A. Further, reduction of ARID1B and PBRM1 protein levels, decreases cell survival and reduces induction of several hypoxia regulated genes in ARID1A deficient MTSs. Our studies have identified PBRM1 as a new vulnerability in ARID1a deficient cancers and which provides a new target for therapeutic strategies.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancers
Jae‐Joong Kim, Jaeik Oh, … Sung‐Yup Cho·Science AdvancesPeer-reviewed·Jun 5, 2026
- Genome-wide CRISPR screen identifies KEAP1 perturbation as a vulnerability of ARID1A-deficient cells
L.-A. Fournier, F. Kalantari, … P. C. Stirling·bioRxiv·Nov 14, 2023
- ARID1A and ARID1B safeguard B cell identity, prevent myeloid transformation and expose therapeutic vulnerabilities in lymphoma
Phyo Nay Lin, Joohyung Park, … George P. Souroullas·bioRxiv·Sep 16, 2025
- Vulnerability of ARID1A deficient cancer cells to pyrimidine synthesis blockade
Z. Li, S. Mi, … G. S. Huang·bioRxiv·Oct 12, 2020
- Integrative analysis of patient-derived tumoroids and ex vivo organoid modeling of ARID1A loss in bladder cancer reveals therapeutic molecular targets
Mathijs P. Scholtes, Maryam Akbarzadeh, … Tokameh Mahmoudi·Cancer LettersPeer-reviewed·Jan 30, 2025
- ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to PARP inhibition in lung cancer
T. Moreno, L. Gonzalez-Silva, … I. Varela·bioRxiv·Jan 10, 2020